https://orcid.org/0000-0001-7748-1891
References
- de Goycoechea D, Dewarrat N, Rothuizen LE, et al. Management of erroneous subcutaneous injection of vincristine. Leuk Lymph. 2020;61(10):2530–2532.
- Schochet SS, Lampert PM, Earle KM. Neuronal changes by intrathecal vincristine. J Neurpath Exp Neurol. 1968;27:645–658.
- Gilbar PJ, Dooley MJ. Review of case reports of inadvertent intrathecal vincristine administration: recommendations to reduce occurrence. Asia-Pacific J Clin Oncol. 2007;3(2):59–65.
- Gilbar PJ. Intrathecal chemotherapy: potential for medication error. Cancer Nurs. 2014;37(4):299–309.
- Gilbar PJ. Inadvertent intrathecal administration of vincristine: time to finally abolish the syringe. J Oncol Pharm Pract. 2020;26(2):263–266.
- Dabrowska-Wojciak I. The death of an infant after the unfortunate intrathecal injection of vincristine. Clin Pract. 2018;15:438–441.
- Stefanou A, Dooley M. A simple method to eliminate the risk of inadvertent intrathecal vincristine administration. J Clin Oncol. 2003;21(10):2044–2047.
- Gilbar PJ, Carrington CV. The incidence of extravasation of vinca alkaloids supplied in syringes or mini-bags. J Oncol Pharm Pract. 2006;12(2):113–118.
- Bruhwiler LD, Schwappach DLB. Safe vincristine use in Switzerland: still a long way to go? J Oncol Pharm Pract. 2020;26(1):51–59.